Laboratory of Vivek Bhalla, MD- Stanford

Molecular Mechanisms of Kidney Disease, @StanfordNeph; Director, @Stanford_HTN; Director, @PreRenal_SU; @KidneyInCVD; @[email protected]

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

Thank you to @rmh199 @StanfordDeptMed for highlighting our work

[Stanford Department of Medicine @StanfordDeptMed]

Join nephrologist Dr. Vivek Bhalla (@BhallaResearch)
& Science Communicator Rebecca Handler (@rmh199) in the lab as he shares a story that began with a single patient’s case of early-onset kidney disease and led to a genetic discovery: https://t.co/khb914xwqE

#Nephrology

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

https://t.co/3UywX30dZZ

[PKD Foundation @PKDFoundation]

Hypertension (high blood pressure) is one of the most common complications of PKD. When hypertension is left untreated, it can further damage the kidneys and increase the risk of heart disease and stroke.

Learn more about managing this symptom of PKD: https://t.co/M8853CJOlU

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@PKDFoundation Congrats @PKDSteve

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@spjuraschek @rmohty Another example of the association out this week

[Circulation @CircAHA]

Study identifies excessive, unregulated aldosterone as a modifiable driver of obesity-related CV risk, highlighting need for trials targeting aldosterone or mineralocorticoid receptors to mitigate early cardiometabolic injury. https://t.co/MfyVGACaQZ

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@spjuraschek @rmohty Agree that isolating the subclinical group would be useful too

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@rmohty @spjuraschek Part of why we do Aldo/renin profiling in all patients with HTN..not just screening for PA but screening for subclinical PA too

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@rmohty @spjuraschek Nor about the sufficiency of MRA therapy with respect to raising renin…(that I’m aware of)….quite plausible that someone has done this work but has not made it to guidelines

Anecdotally, MRAs work very well for BP control including monotherapy in this population. 3/n

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@rmohty @spjuraschek No evidence that targeting this group with MRAs reduces those endpoints. 2/n

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

Amazing. Remembering Michelle Winn’s work that pointed the way to this moment. https://t.co/MfzP1vFN88

[Katalin Susztak @KSusztak]

TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198 - The Lancet https://t.co/QN5K71wUwZ @TheLancet

[JCI insight @JCI_insight]

This month marks 10 years of JCI Insight!
A special shoutout to authors, editors, reviewers, readers, and all those dedicated to biomedical research, ranging from preclinical to clinical studies. This video highlights selected covers through the years.

—
Music: Bensound; License code: LDOZSSOUYFKAOLR8; Artist: Theatre Of Delays

@Eickelberg_MD

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@proychaudhuryMD @ASNKidney Thank you for your leadership and happy new year 🎊

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

https://t.co/MKq5FrsXUG

[Stanford Nephrology @StanfordNeph]

Please help us bring hope and light into this Holiday Season.

One of our @StanfordNeph @StanfordAbdTxp faculty families is working to save their child’s life from a rare genetic condition.

Please read, share and support.

https://t.co/naGsRMZb2u

[Stanford Nephrology @StanfordNeph]

Please help us bring hope and light into this Holiday Season.

One of our @StanfordNeph @StanfordAbdTxp faculty families is working to save their child’s life from a rare genetic condition.

Please read, share and support.

https://t.co/naGsRMZb2u

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@Joseph_C_Wu @StanfordDeptMed @StanfordMed @ScienceTM @StanfordCVI @Stanford_ChEMH @stanfordimmuno @CellStanford @GreenstoneBio @brucegoldman Congrats, @Joseph_C_Wu

[Joseph C Wu, MD, PhD @Joseph_C_Wu]

Congrats @StanfordMed scientists for publishing @ScienceTM showing how mRNA-based COVID vaccines can cause myocarditis via CXCL10-TNFy signaling axis.
@StanfordCVI @Stanford_ChEMH @StanfordDeptMed @stanfordimmuno @CellStanford @GreenstoneBio @brucegoldman https://t.co/WAYTk63tuM

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@kidneyomicsamps @WashU Congrats!

[Eugene Yang @DrEugeneYang]

Thanks to Jordy and Tammy for their leadership on this important statement! @jordy_bc @TammyBradyMD

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

who sought to sift through these factors to demonstrate that this could indeed work. There is lots to still do, both in lab and in clinic, and there are risks/benefits to calculate, but for those families suffering with a rare disease, this may be possible @StanfordNeph 4/x.

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

Dissecting through renal physiology in the context of patient care is difficult but eminently valuable. Inspired by the landmark work of Hoorn et al., https://t.co/Rv1fbQQO9P showing the effect of tacrolimus on phosphorylated NCC, we sought to understand if the use of CNIs 1/x.

[Annals of Internal Medicine: Clinical Cases @AnnalsofIMCC]

Gitelman syndrome (GS) is a rare, autosomal-recessive salt-losing tubulopathy often requiring lifelong electrolyte supplementation. A new case report describes a patient with GS who initiated tacrolimus, a calcineurin phosphatase inhibitor, after orthotopic heart transplantation. The patient achieved normokalemia and improved blood pressure without needing potassium supplements. Read the full text for free: https://t.co/Xa6YtIxj9g @AHAScience #AHAJournals

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

but there are only historical controls and multiple confounding factors in patients who receive tacrolimus (diuretics, PJP prophylaxis, PPIs, RAASi, etc). I'm thankful to Ms. Halee Yue @UCLAHealth and Dr. Martina Cacciapuoti @MartiCacciaNeph 3/x